Verastem Catapults To Mid-stage Development with Pfizer Licensing Deal

The Massachusetts-based cancer stem cell company has struck two deals in as many days in an effort to move compounds into the clinic for various types of cancers and multiple targets.

In a week filled with deal activity, Cambridge, Mass.-based cancer stem cell company Verastem Inc. held an R&D day to discuss the changes that have propelled it from pre-clinical stage activity to a clinical-stage company with a compound ready to enter Phase II.

Earlier this week on July 11, Verastem announced that it had in-licensed Pfizer Inc.’s focal adhesion kinase (FAK) inhibitor,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D

Adaptive Clinical Trials Require ‘Clear And Compelling Justification’

 
• By 

A draft international guideline on using adaptive trial designs says sponsors should provide a clear rationale for using such designs to address the potential ‘tension’ between the confirmatory nature of late-stage trials and the flexibility introduced by mid-trial adaptations.

Denmark Sets New EU Benchmark With 14-Day Clinical Trial Review Timeline

 
• By 

Denmark is shaking up clinical trial timelines with a new process for reviewing applications for early-phase mono-national trials that is twice as fast as the standard timelines in the EU and the UK.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.